Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Capivasertib for PIK3CA/AKT1/PTEN–Altered Breast Cancer With Jason Mouabbi, MD, and Carlos Doti, MD
MP3•Episode home
Manage episode 397126575 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations. In this interview, Editorial Board member Dr. Jason Mouabbi speaks with Dr. Carlos Doti, Head of Medical Affairs, US Oncology at AstraZeneca, about the significance of the approval, its dosing schedule, AstraZeneca's approach towards patient education and adverse event management, and the future of capivasertib in different treatment settings.
…
continue reading
348 episodes
MP3•Episode home
Manage episode 397126575 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations. In this interview, Editorial Board member Dr. Jason Mouabbi speaks with Dr. Carlos Doti, Head of Medical Affairs, US Oncology at AstraZeneca, about the significance of the approval, its dosing schedule, AstraZeneca's approach towards patient education and adverse event management, and the future of capivasertib in different treatment settings.
…
continue reading
348 episodes
所有剧集
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.